Injectable triamcinolone suspension approved for use in eye surgery

Huenenberg, Switzerland-Alcon Inc. announced that the FDA has approved triamcinolone acetonide injectable suspension 40 mg/ml (Triesence), a preservative-free synthetic corticosteroid for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

While the product’s active ingredient, triamcinolone acetonide, has been used for many years to treat retinal disease, the new approval brings ophthalmologists a sterile, preservative-free formulation of the compound specifically developed for use in the eye to treat various retinal inflammatory conditions, said Alcon in a prepared statement.